Workflow
Agios Pharmaceuticals(AGIO) - 2025 Q1 - Quarterly Report
AGIOAgios Pharmaceuticals(AGIO)2025-05-01 14:26
Transcript
Slide

Financial Performance - The net loss for the three months ended March 31, 2025, was 89.3million,comparedtoanetlossof89.3 million, compared to a net loss of 81.5 million for the same period in 2024, resulting in an accumulated deficit of 238.2millionasofMarch31,2025[89].−TotalrevenueforthethreemonthsendedMarch31,2025,was238.2 million as of March 31, 2025[89]. - Total revenue for the three months ended March 31, 2025, was 8.726 million, an increase of 0.5millioncomparedto0.5 million compared to 8.189 million in the same period of 2024[120]. - Total operating expenses for the three months ended March 31, 2025, were 115.355million,anincreaseof115.355 million, an increase of 15.1 million compared to 100.261millioninthesameperiodof2024[121].−ResearchanddevelopmentexpensesforthethreemonthsendedMarch31,2025,totaled100.261 million in the same period of 2024[121]. - Research and development expenses for the three months ended March 31, 2025, totaled 72.743 million, an increase of 4.1millioncomparedto4.1 million compared to 68.620 million in the same period of 2024[123]. - Net cash used in operating activities for the three months ended March 31, 2025, was 111.5million,comparedto111.5 million, compared to 99.9 million for the same period in 2024[132][133]. - Cash provided by investing activities was 112.6millionforthethreemonthsendedMarch31,2025,comparedto112.6 million for the three months ended March 31, 2025, compared to 124.6 million in 2024[134]. - Interest income, net for the three months ended March 31, 2025, was 16.087million,anincreasefrom16.087 million, an increase from 8.889 million in the same period of 2024[124]. - As of March 31, 2025, the company had cash, cash equivalents, and marketable securities totaling 1.4billion[131].ProductDevelopmentandApprovals−PYRUKYND®isapprovedbytheFDAfortreatinghemolyticanemiainadultswithPKdeficiency,andasupplementalnewdrugapplicationwassubmittedfortreatingalpha−orbeta−thalassemia,withaPDUFAgoaldateofSeptember7,2025[81].−ThecompanyisevaluatingPYRUKYND®inaphase3clinicaltrialforsicklecelldiseaseanddevelopingothercandidatesliketebapivatforlower−riskmyelodysplasticsyndromes[82].−PYRUKYND®receivedFDAapprovalfortreatinghemolyticanemiainadultswithPKdeficiencyandmarketingauthorizationintheEUandGreatBritain[99].−ThecompanysubmittedansNDAtotheFDAforPYRUKYND®fortreatingnon−transfusiondependentandtransfusion−dependentalpha−orbeta−thalassemia,withaPDUFAgoaldateofSeptember7,2025[99].−TebapivathasbeengrantedorphandrugdesignationforthetreatmentofMDSbytheFDA,withaphase2clinicaltrialexpectedtobegininmid−2025[114].ClinicalTrialsandResults−IntheENERGIZEtrial,42.31.4 billion[131]. Product Development and Approvals - PYRUKYND® is approved by the FDA for treating hemolytic anemia in adults with PK deficiency, and a supplemental new drug application was submitted for treating alpha- or beta-thalassemia, with a PDUFA goal date of September 7, 2025[81]. - The company is evaluating PYRUKYND® in a phase 3 clinical trial for sickle cell disease and developing other candidates like tebapivat for lower-risk myelodysplastic syndromes[82]. - PYRUKYND® received FDA approval for treating hemolytic anemia in adults with PK deficiency and marketing authorization in the EU and Great Britain[99]. - The company submitted an sNDA to the FDA for PYRUKYND® for treating non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia, with a PDUFA goal date of September 7, 2025[99]. - Tebapivat has been granted orphan drug designation for the treatment of MDS by the FDA, with a phase 2 clinical trial expected to begin in mid-2025[114]. Clinical Trials and Results - In the ENERGIZE trial, 42.3% of patients on PYRUKYND® achieved a hemoglobin response compared to 1.6% in the placebo group, demonstrating statistical significance (p<0.0001) with 194 patients enrolled[102]. - In the ENERGIZE-T trial, 30.4% of patients on PYRUKYND® achieved a transfusion reduction response compared to 12.6% in the placebo group (p=0.0003), with 258 patients enrolled[105]. - The RISE UP study showed that 46.2% and 50.0% of patients in the 50 mg and 100 mg arms, respectively, achieved a hemoglobin response compared to 3.7% in the placebo arm (p=0.0003 and 0.0001) with 79 patients enrolled[109]. - In the ACTIVATE-kidsT study, 28.1% of patients in the mitapivat arm achieved the primary endpoint of transfusion reduction response, compared to 11.8% in the placebo arm[111]. - In the ACTIVATE-kids study, 31.6% of patients in the mitapivat arm achieved a hemoglobin response, while 0% of patients in the placebo arm achieved this response[113]. - The company is evaluating PYRUKYND® in clinical trials for SCD and pediatric patients with PK deficiency[99]. - The company has updated clinical trial protocols to include monthly monitoring of liver tests for the first six months of treatment due to potential hepatocellular injury risks[107]. - The company expects to announce topline data for the phase 3 portion of the RISE UP trial in late 2025, with a potential U.S. commercial launch in 2026 if approved[109]. Business Transactions and Collaborations - The sale of the oncology business to Servier was completed for approximately 1.8 billion in cash, with additional contingent payments based on future approvals and sales[83]. - In September 2024, the company recognized income of 200.0millionfromtheVorasidenibMilestonePaymentfollowingFDAapprovalforvorasidenib[86].−Thecompanyrecognizedincomeof200.0 million from the Vorasidenib Milestone Payment following FDA approval for vorasidenib[86]. - The company recognized income of 889.1 million from the sale of Vorasidenib Royalty Rights to Royalty Pharma, net of fees[87]. - The company entered into a distribution agreement with NewBridge Pharmaceuticals for PYRUKYND® in the GCC region, expanding its market reach[91]. - The company entered a distribution agreement with NewBridge Pharmaceuticals for PYRUKYND® commercialization in the GCC region[100]. Future Outlook and Risks - The company expects to continue generating revenue from product sales and potential milestone payments from collaborations or licensing agreements in the future[92]. - Research and development expenses are expected to increase as product candidate development programs progress, with significant uncertainty regarding costs and timelines[95]. - The company has historically incurred significant operating losses and expects to continue incurring significant expenses until achieving profitable results[89]. - The company expects expenses to increase as it continues research, development, and commercialization of its product candidates, including PYRUKYND®[136]. - Future capital requirements will depend on various factors, including the success of product sales and potential royalty payments from Retained Earn-Out Rights[139]. - The company is exposed to market risks related to interest rates and foreign currency exchange rates, with minimal liabilities in foreign currencies as of March 31, 2025[142][145]. - The company anticipates financing cash needs primarily through cash on hand, potential royalty payments, and product sales until substantial revenue is generated[139]. - The company may need additional capital resources to fund operating plans and capital expenditures, which could involve dilution of stockholder ownership[139].